



**Health and Community Services**

**MACITENTAN (OPSUMIT) 10 MG TABLET**

For the treatment of patients with Group 1 pulmonary arterial hypertension (PAH) with World Health Organization (WHO) functional class II, III or IV.

**Clinical Note:**

- The diagnosis of PAH should be confirmed by right heart catheterization.

**Claim Notes:**

- Must be prescribed by, or in consultation with, a physician experienced in the treatment of PAH.
- Combined use of more than one endothelin receptor antagonists will not be reimbursed.
- The maximum dose of macitentan that will be reimbursed is 10 mg daily.
- Approval period: Long term.

**Please visit the link below if you require our standard special authorization form:**

[http://www.health.gov.nl.ca/health/prescription/standard\\_specauth\\_form.pdf](http://www.health.gov.nl.ca/health/prescription/standard_specauth_form.pdf)

**Updated July 2022**